Tools · DRREDDY.NS
Dr. Reddy's Laboratories Limited, taken apart.
Four panels built from the reported annual accounts, then the rest of the engine. Every figure below is Dr. Reddy's Laboratories Limited’s own filing, not an estimate of ours.
Income statement
Revenue mix
Peer comparison
Analyst ratings
What if I had bought
Sentiment
Chart patterns
Income statement, four years
Read across, not down. Each line is shown for four fiscal years, so the direction matters more than any single column.
| Line | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | ₹33,593 Cr | ₹32,554 Cr | ₹27,916 Cr | ₹24,588 Cr |
| Cost of revenue | ₹15,867 Cr | ₹13,511 Cr | ₹11,556 Cr | ₹10,654 Cr |
| Gross profit | ₹17,726 Cr | ₹19,043 Cr | ₹16,361 Cr | ₹13,934 Cr |
| Operating expenses | ₹12,714 Cr | ₹11,841 Cr | ₹9,830 Cr | ₹8,029 Cr |
| Operating income | ₹5,012 Cr | ₹7,201 Cr | ₹6,531 Cr | ₹5,905 Cr |
| Net income | ₹4,285 Cr | ₹5,654 Cr | ₹5,568 Cr | ₹4,507 Cr |
| Diluted EPS | 51.42 | 67.78 | 66.92 | 54.17 |
Net income and earnings per share moved together (-4.9% and -5.1%), so the share count barely changed over the period.
The rest of the engine
The panels above are built from filings. These run against the live engine.
/screener
Screener
Preset screens run against the live universe
Value, growth, quality and momentum presets
/markets
Markets
Indices, sector performance and the yield curve
One request per panel, cached for ten minutes
/dcf-calculator
DCF calculator
Value the company on the cash it produces
The projection period and terminal growth are yours
/watchlist
Watchlist
Follow symbols with a live price and day change
Needs an account
/portfolio
Portfolio
Holdings with unrealised profit and loss
Totalled per currency — needs an account
/learn
Learn
Guides, a glossary and the assistant
Explains the scorecard this site actually runs